Drug intelligence / Profile preview

E coli vaccine 3

Development stage: Unknown
Lead developer: Pfizer
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

E coli vaccine 3 is an investigational vaccine candidate developed by Pfizer to prevent infections caused by pathogenic strains of Escherichia coli. It is one of several candidates (including E coli vaccines 1, 2, 4, and 5) being evaluated in a Phase 1 clinical trial (NCT07122986) to assess safety, tolerability, and immunogenicity in healthy adults aged 18-64. The vaccine is composed of killed or partial bacterial components that are non-infectious and is administered via intramuscular injection on a two-dose schedule at 0 and 6 months.

Other names: escherichia coli vaccine 3

Beyond the preview

Go deeper on E coli vaccine 3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on E coli vaccine 3.

Explore the full profile